Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/31065
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFasero, Maria-
dc.contributor.authorQuereda, Francisco-
dc.contributor.authorAndraca, Leire-
dc.contributor.authorCoronado, Pluvio J.-
dc.contributor.authorHT Eligibility Criteria Group-
dc.contributor.otherDepartamentos de la UMH::Salud Pública, Historia de la Ciencia y Ginecologíaes_ES
dc.date.accessioned2024-02-05T12:37:52Z-
dc.date.available2024-02-05T12:37:52Z-
dc.date.created2023-08-
dc.identifier.citationMenopause. 2023 Aug 1;30(8):873-880es_ES
dc.identifier.issn1530-0374-
dc.identifier.issn1072-3714-
dc.identifier.urihttps://hdl.handle.net/11000/31065-
dc.description.abstractImportance and Objective: Menopausal hormone therapy (HT) is widely used, and there are several statements of international scientific societies to guide prescribers; however, a summary of existing literature about possible drug interactions with HT does not exist, although many midlife women take medications for other conditions. Therefore, our objective was to create a document that presents and synthesizes the most relevant interactions. The impact of the interaction itself and the number of candidates for HTwho are likely to use other treatments are considered based on the best available evidence. Methods: A systematic review was performed to determine the best evidence of interaction effects on relevant outcomes of interest for decision making. Aworking framework was developed to formulate explicit and reasoned recommendations according to four predefined categories for coadministration: (1) can be used without expected risks, (2) acceptable use (no evidence of negative interaction), (3) alternative treatment should be considered, and (4) nonuse without express justification. The project protocolwas registered in the Open Science Framework platform (doi: 10.17605/OSF.IO/J6WBC) and in PROSPERO (registration number CRD42020166658). Results: Studies targeting our objective are scarce, but 23 pharmacological groups were assigned to one of the predefined categories of recommendation for concomitant use of HT. Vaginal HTwas assigned to category 1 for 21 of the analyzed pharmacological groups. For oral and transdermal HT (estrogen-only or combined) and tibolone, there were 12 pharmacological groups assigned to category 1, 12 to category 2, 5 to category 3, and 4 to category 4. Results are shown in crossed-tables that are useful for counseling and prescription. Discussion and conclusions: Available evidence of HT interactions with other drugs is scarce and mainly indirect. It comes from biological plausibility, knowledge of extensive concomitant use without reported incidents, and/or extrapolation from hormonal contraception, but there are pharmacological groups in all categories showing that information is useful. These eligibility criteria summarize it and can help in the decision process of HT coadministration with other drugs. Decisions should be taken based on these recommendations but also individualized risk/benefit evaluation, according to underlying pathology, patient's clinical requirements, and the existence or nonexistence of alternatives.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent8es_ES
dc.language.isoenges_ES
dc.publisherLippincott, Williams & Wilkinses_ES
dc.rightsinfo:eu-repo/semantics/closedAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectBiological plausibilityes_ES
dc.subjectCoadministration drugses_ES
dc.subjectMedical eligibility criteriaes_ES
dc.subjectMenopausal hormone therapyes_ES
dc.subjectPharmacological interactionses_ES
dc.titlePharmacological interactions and menopausal hormone therapy a reviewes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1097/GME.0000000000002219es_ES
Appears in Collections:
Artículos Salud Pública, Historia de la Ciencia y Ginecología


no-thumbnailView/Open:

 Pharmacological interactions and menopausal hormone therapy a review.pdf



152,53 kB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???